Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria

Bone

Volumn 85, Issue , 2016, Pages 55-58

  Wong, Phillip ^a,b,c   Polkinghorne, Kevan ^b,c   Kerr, Peter G ^b,c   Doery, James C G ^b,c   Gillespie, Matthew T ^a,c   Larmour, I ^b   Fuller, Peter J ^a,b,c   Bowden, Donald K ^b   Milat, Frances ^a,b,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Deferasirox; Disorders of calcium; Hypercalciuria; Iron overload; Thalassemia

Indexed keywords

CREATININE; DEFERASIROX; DEFEROXAMINE; BENZOIC ACID DERIVATIVE; CALCIUM; TRIAZOLE DERIVATIVE;

ADULT; AGE; ANALYTICAL PARAMETERS; ARTICLE; BETA THALASSEMIA; CALCIUM URINE LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; FEMALE; GENDER; HEMOGLOBIN E-BETA THALASSEMIA; HEMOGLOBIN H DISEASE; HUMAN; HYPERCALCIURIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SICKLE CELL ANEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; URINE CALCIUM TO CREATININE RATIO; CASE CONTROL STUDY; CHEMICALLY INDUCED; URINE;

ADULT; BENZOATES; CALCIUM; CASE-CONTROL STUDIES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERCALCIURIA; MALE; TRIAZOLES;

EID: 84956673842     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.01.011     Document Type: Article

References (23)

1. Porter J.B. Practical management of iron overload. Br. J. Haematol. 2001, 115:239-252.
2. Wong P., Fuller P.J., Gillespie M.T., et al. Thalassemia bone disease: a 19 year longitudinal analysis. J. Bone Miner. Res. 2014, 25.
3. Wong P., Fuller P.J., Gillespie M.T., et al. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporosis International: A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013, 24:1965-1971.
4. Milat F., Wong P., Fuller P.J., et al. A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. J. Bone Miner. Res. 2012, 27:219-222.
5. Cappellini M.D., Bejaoui M., Agaoglu L., et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin. Ther. 2007, 29:909-917.
6. Cappellini M.D., Cohen A., Piga A., et al. Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006, 107:3455-3462.
7. Taher A., El-Beshlawy A., Elalfy M.S., et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur. J. Haematol. 2009, 82:458-465.
8. Cappellini M.D., Bejaoui M., Agaoglu L., et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years follow-up. Blood 2011, 118:884-893.
9. Taher A., Cappellini M.D., Vichinsky E., et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br. J. Haematol. 2009, 147:752-759.
10. Naderi M., Sadeghi-Bojd S., Valeshabad A.K., et al. A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatr. Hematol. Oncol. 2013, 30:748-754.
11. Efthimia V., Neokleous N., Agapidou A., et al. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience. Ann. Hematol. 2013 Jan, 92(2):263-265.
12. Wills M.R. The urinary calcium-creatinine ratio as a measure of urinary calcium excretion. J. Clin. Pathol. 1969, 22:287-290.
13. Price C.P., Newall R.G., Boyd J.C. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin. Chem. 2005, 51:1577-1586.
14. Wong P., Fuller P.J., Gillespie M.T., et al. Thalassemia bone disease: a 19-year longitudinal analysis. J. Bone Miner. Res. 2014, 29:2468-2473.
15. Wong P., Fuller P.J., Gillespie M.T., et al. The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia. Osteoporos. Int. 2014, 25:597-604.
16. Dunstan D.W., Zimmet P.Z., Welborn T.A., et al. The Australian diabetes, obesity and lifestyle study (AusDiab) - methods and response rates. Diabetes Res. Clin. Pract. 2002, 57:119-129.
17. Economou M., Printza N., Teli A., et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010, 123:148-152.
18. Quinn C.T., Johnson V.L., Kim H.Y., et al. Renal dysfunction in patients with thalassaemia. Br. J. Haematol. 2011, 153:111-117.
19. Bhandari S., Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur. J. Haematol. 2012, 89:187-197.
20. Atamna H., Walter P.B., Ames B.N. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. Arch. Biochem. Biophys. 2002, 397:345-353.
21. Rossi F., Perrotta S., Bellini G., et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 2014, 99:1876-1884.
22. Casale M., Citarella S., Filosa A., et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with beta-thalassemia major. Am. J. Hematol. 2014, 89:1102-1106.
23. Ricchi P., Ammirabile M., Costantini S., et al. Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters. Ann. Hematol. 2014, 93:525-527.